Skip to main content

View full-text article in PMC

. 2018 Mar 27;9(23):16297–16310. doi: 10.18632/oncotarget.24631

Table 2. Relation of ALK5-FL, ALK5-ICD, pSMAD2/3 and PAI-1 protein levels to categorized clinicopathological parameters in non-ccRCC.

Parameter	ALK5-FL			ALK5-ICD			pSMAD2/3			PAI-1
Parameter	n^a	Mean Rank	P-Value^b	n^a	Mean Rank	P-Value^b	n^a	Mean Rank	P-Value^b	n^a	Mean Rank	P-Value^b
Grade
I (I+II)	33	28.58		33	32.56		33	27.82		33	30.82
			0.632			0.113			0.384			0.495
II (III+IV)	25	30.72		25	25.46		25	31.43		25	27.76
TNM Stage
Early Stage (I+II)	40	28.38		40	32.16		40	27.58		40	29.88
			0.449			0.073			0.196			0.801
Advanced Stage (III+IV)	18	32		18	23.58		18	33.78		18	28.67
Tumor size (mm)
<70	35	28.74		35	29.21		35	28.23		35	30
			0.674			0.874			0.479			0.781
>70	23	30.65		23	29.93		23	31.43		23	28.74

^a Number of patients.

^b Groups were compared using Mann-Whitney U test (significant at P<0.05).